Tvardi Therapeutics is trading at $1.07, up 6.99%, amid a rise in biotech shares, though the cause of its gain is unclear. - The company’s October 14 announcement concerned management participating in a healthcare conference on October 20, not a clinical or regulatory milestone. - The earlier Phase 2 IPF trial update covered results announced in 2025 and was not a new October 15 catalyst.